Proimmune has announced the introduction of the Reveal immunogenicity system, a suite of services for development and testing of biologics with reduced immunogenicity.
This suite of services helps to design and select biological drug leads at the preclinical stage, thereby minimising the risk of adverse drug reactions related to unwanted immunogenicity.
The immunogenicity of biological drugs can often be a significant obstacle in the development of successful new therapies.
Unwanted immunogenicity can manifest itself particularly through anti-drug antibody (ADA) responses.
These responses can lead to allergic reactions, reduction or neutralisation of the activity of the drug and, in some cases, cross-reactive immune responses, which could lead to serious adverse events.
ProImmune's Reveal system combines cell-free HLA-peptide binding assays for more than 50 class II HLA alleles, with highly-sensitive T cell proliferation assays.
This combination enables the creation of a detailed profile of the helper T cell immune response to one or more drug leads.
The role of helper T cells is known to be of critical importance in controlling unwanted anti-drug antibody responses.
If desired, the leads analysed can then be re-engineered to remove unwanted helper T cell epitopes and produce a re-validated drug lead with improved immunogenicity risk.
